TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02896699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Intervention Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study: NCT00739765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: 14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Description: Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
Study: NCT01968226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] RDG-K5
Description: Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
Study: NCT02010138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: small-extent peeling
Description: The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: large-extent peeling
Description: The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
Study: NCT02456506

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fraction IMRT
Study: NCT03461575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: cyclosporine 0.02%, trehalose 3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: cyclosporine 0.05%
Study: NCT02009566

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Abdominal radiographs with microfabricated tags
Description: Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
Study: NCT00151177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive continuous positive airway pressure ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP-treatment
Description: night time CPAP-mask ventilation
Study: NCT03461575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moisview
Description: trehalose 3%
Study: NCT01320215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted promontofixation
Description: Sacrohysteropexy with robotic assistance (da Vinci robot)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-robot assisted promontofixation
Description: Laparoscopic sacrohysteropexy, without robot assistance
Study: NCT01077817

Intervention type: DRUG
Intervention: Etidronate

Intervention type: DRUG
Intervention: Etidronate

Intervention type: DRUG
Intervention: Ibandronate

Intervention type: DRUG
Intervention: Ibandronate

Intervention type: DRUG
Intervention: Ibandronate

Intervention type: DRUG
Intervention: Risedronate

Intervention type: DRUG
Intervention: Risedronate

Intervention type: DRUG
Intervention: Risedronate

Intervention type: DRUG
Intervention: Raloxifene

Intervention type: DRUG
Intervention: Raloxifene

Intervention type: DRUG
Intervention: Raloxifene
Study: NCT00362817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
Study: NCT01294566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322888
Description: 1 mg, 5 mg or 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322888
Description: 1 mg, 5 mg or 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules
Study: NCT02075606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide acetate
Description: Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
Study: NCT04510129

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Study: NCT00151177

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CPAP-treatment
Description: night time CPAP-mask ventilation
Study: NCT03044444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrus extract
Description: Participants will receive either a low or high dose citrus extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citrus extract
Description: Participants will receive either a low or high dose citrus extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants will receive 500mg of maltodextrin
Study: NCT02908711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% ropivacaine
Description: Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
Study: NCT03070626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOp®
Description: No preoperative drink.
Study: NCT01093014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential low-force and high-force muscle stimulation
Description: Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
Study: NCT02767076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional paramedian spinal anesthesia
Description: land mark guided paramedian spinal anesthesia
Study: NCT00833365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
Study: NCT04339374

Intervention type: DEVICE
Intervention: Photoacoustic imaging, photoacoustic microscopy
Description: * Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~* The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~* The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants

Intervention type: DEVICE
Intervention: Photoacoustic imaging, photoacoustic microscopy
Description: * Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~* The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~* The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants

Intervention type: DEVICE
Intervention: Endorectal photoacoustic imaging probe
Description: * Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants

Intervention type: DEVICE
Intervention: Endorectal photoacoustic imaging probe
Description: * Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants
Study: NCT04580901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy
Description: Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
Study: NCT03823911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Description: All approved direct-acting antivirals for hepatitis C will be used as the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Description: All approved direct-acting antivirals for hepatitis C will be used as the intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI to assess for myocardial function and fibrosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI to assess for myocardial function and fibrosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI to assess for myocardial function and fibrosis
Study: NCT00258895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL®: DTaP
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL®: DTaP
Description: 0.5 mL, Intramuscular
Study: NCT00982618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1% Lidocaine 1mg/kg/hr IV drip x 48hr

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Block
Description: 0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA Morphine
Description: PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Study: NCT02331004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention for fine motor skills
Description: Implementation of an well known activity to improve the function of upper extremities

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Support to activities of daily living
Description: Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
Study: NCT02431663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous administration in continuous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous administration in continuous
Study: NCT00834834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DBT
Description: One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
Study: NCT03532711

Intervention type: DRUG
Intervention: fluorouracil
Description: chemotherapy treated patients
Study: NCT03863834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InModeRF
Description: InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
Study: NCT04151407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Study: NCT01583712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Description: Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscope
Description: Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
Study: NCT04009577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Description: LEM tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Description: LEM tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Description: LEM tablet.
Study: NCT03802149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: 90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
Study: NCT01703897

Intervention type: DEVICE
Intervention: Manometry and Impedance analysis
Study: NCT02165761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE® Hybrid Vascular Graft

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-heparin bonded synthetic graft
Study: NCT02020616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3053102
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3053102
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide ER
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide ER
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally (PO)
Study: NCT04215471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 Antibody SHR-1316
Description: Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
Study: NCT02709863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 1-1.5 MAC, inhalation route, during operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: 1-1.5 MAC, inhalation route, during operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 6-10 mg/kg/h, iv infusion, during operation
Study: NCT03070483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 5000 IU cholecalciferol with 1000 mg calcium citrate daily
Study: NCT01788930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Study: NCT00786006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3
Description: FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
Study: NCT02425917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: neuromuscular electrostimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPC-Calf
Description: IPC used on calf with or without geko
Study: NCT01036412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Chlorhexidine Gluconate Gel
Description: Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
Study: NCT03209037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study: NCT04189770

Intervention type: DEVICE
Intervention: Accelerometer
Description: Wear accelerometer

Intervention type: OTHER
Intervention: Ecological Momentary Assessment
Description: Complete EMA questionnaire

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT02315469

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Complete pre-operative geriatric assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00658996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofLens DD Toric
Description: daily disposable wear contact lens for 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision Focus Dailies Toric Contact Lens
Description: daily disposable wear contact lens for 2 weeks
Study: NCT01460563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
Study: NCT04510129

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoPrism™ assay
Description: OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
Study: NCT01886482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Description: high protein diet